Abbott Laboratories (ABT), a healthcare company with a market cap of $217 billion, is set to announce its fiscal Q4 earnings for 2025. Analysts expect a profit of $1.50 per share, up 11.9% from the year-ago quarter. For the full fiscal year, ABT is projected to report a profit of $5.15 per share, a 10.3% increase from the previous year. Shares of ABT have gained 8.8% over the past 52 weeks, underperforming the S&P 500 Index and the State Street Health Care Select Sector SPDR ETF.

In October, ABT shares dropped 2.9% after posting mixed Q3 earnings. Net sales rose 6.9% year-over-year to $11.4 billion, but missed estimates due to a decline in diagnostic products revenue. However, adjusted EPS of $1.30 met expectations. Analysts are optimistic about ABT, with an overall “Strong Buy” rating and a mean price target of $146.69, representing a 17.5% potential upside from current levels.

Read more at Barchart: What You Need to Know Ahead of Abbott Laboratories’ Earnings Release